There are multiple potential applications for circulating tumor (ct)DNA in kidney cancer. The post-nephrectomy remission, adjuvant therapy decision, and monitoring for response or progression on ...

More than 70 percent of Japanese renal cell carcinoma patients have a specific genetic mutation pattern that is rarely found ...

This is a prospective study of all patients with metastatic RCC unselected for high-risk features, registered at our center between September 2023 and August 2024. Baseline clinicopathologic details ...

In RCC, a phase I study of a neoantigen-targeting personalized cancer vaccine in the adjuvant setting was successful in eliciting antigen-specific and tumor-directed immune responses. 77 These studies ...

For patients with primary localized renal cell carcinoma (RCC), especially those who aren’t good candidates for surgery, noninvasive or minimally invasive ablative treatments have emerged as important ...

Prospective evidence supports SABR as a valid option for localized RCC and suggests SABR with or without immunotherapy has promise in the metastatic setting. Challenging notions of renal cell ...

In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell responses, among other factors. Among treatment-naive patients with metastatic ...

A personalized cancer vaccine targeting neoantigens in high-risk renal cell carcinoma (RCC) demonstrates promising results, with no disease recurrence in any of the nine participants over a 40.2-month ...

In RCC with metastases after nephrectomy, cancer-specific survival was higher if cancer spread to the adrenal gland or contralateral kidney. In renal cell carcinoma (RCC), both the timing and the ...

Cystic renal cell carcinoma is a rare type of cancer. A person may develop cystic renal cell carcinoma if they have treatment for the last stages of kidney failure. Cystic renal cell carcinoma (CRCC) ...